HISTALIM

HISTALIM is The First European Laboratory to Adopt the Vectra® Polaris™ Automated Quantitative Pathology Imaging System Developed by PerkinElmer, Inc. Which Enables Scientists to Analyze up to 7 Markers on 1 Single Slide

In 2016 HISTALIM observed an increasing demand from its customers and
partners for multiplex imagery. The company leads several development
programs and is involved in numerous clinical trials in the field of
cancer immuno therapies. In this particular area HISTALIM performs
studies which aim at characterizing the tumor microenvironment and its
interaction with immune cells.

The extraction of quantitative data on a high number of markers despite
the limited availability of biological material represents a major stake
in this kind of study. Another challenge deals with the analysis of the
interaction between several markers involved in immune mechanisms on one
single slide.

Histalim chose to bring enhanced precision and efficacy in biopsies and
tissue samples by utilizing the Vectra Polaris technology. The Vectra
Polaris system is the first slide scanner which enables multiplex
analysis on histopathological markers.

Dr. Laurent LAGUERRE (HISTALIM), who led the discussions with
PerkinElmer, said: “We have been impressed by this technology
combining multiplex imagery with slide scanning. This is the most
advanced research solution for digital pathology on IHC multiplex
labelling.
”

With slides containing up to 7 colors, the histopathologists
collaborating with Histalim will then be able to bring all their
expertise, whether they are located in house or at the client’s site.

Mr. Terry Lo, General Manager, Quantitative Pathology, PerkinElmer,
declared: “We are very proud of this agreement which makes HISTALIM
our first Europeancustomer. Thisrelationship represents
a huge accelerator for the development of Vectra Polaris technology in
Europe since HISTALIM is engaged in many clinical trials in
immuno-oncology.
”

The Vectra Polaris system was officially launched internationally on 26th
of January 2017.

About HISTALIM :
HISTALIM is a European leading company in
the field of histopathology services, and tissue based assays. Ranging
from neurosciences to toxicity assessment, from the characterization of
therapeutic antibodies to the evaluation of implantable medical
devices..., the company focus on accompanying each client to provide
each of them with a perfectly controlled service.
The company knows
an important growth due to its strategic position in the development of
immuno-oncology and biotherapies as a service provider.